Venous Thromboembolism (VTE) News and Information

Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

Dabigatran etexilate as effective and safe as enoxaparin in preventing venous thromboembolism (VTE) after total hip replacement surgery and significantly reduced the combined endpoint of major VTE and VTE-related death

Milestone results in RE-COVER™ study – novel oral direct thrombin inhibitor dabigatran etexilate – as effective as well controlled warfarin with less bleeding in treatment of acute venous thromboembolism

Positive UK health technology appraisal for novel oral anticoagulant Pradaxa® (dabigatran etexilate)